Cohance Lifesciences Sees Credit Rating Withdrawal Amidst Q1 Loss

Cohance Lifesciences reported a net loss of Rs 45.19 crore in Q1 FY27, a shift from a profit of Rs 46.40 crore in the same quarter last year.

Reader Takeaway: Rating withdrawal raises concerns, while Q1 loss and USFDA observations require close investor monitoring.

What just happened

CRISIL Ratings Limited has withdrawn its credit ratings for Cohance Lifesciences Limited's bank facilities upon the company's request. Previously, CRISIL had downgraded the ratings to 'CRISIL BB/Stable / CRISIL A4+' and flagged the company as 'Issuer Not Cooperating' due to a lack of information. Despite multiple attempts, Cohance Lifesciences failed to provide the necessary details to CRISIL.

Why this matters

The withdrawal of ratings, especially under a non-cooperative status, can signal potential governance or transparency issues to the market. However, Cohance Lifesciences has clarified that this withdrawal will not affect its existing credit facilities. The company highlighted that its higher-limit facilities are supported by valid ratings from India Ratings and Research Private Limited.

The backstory

CRISIL's decision to migrate ratings to 'Issuer Not Cooperating' indicates a breakdown in communication. This was a significant downgrade from previous ratings of 'CRISIL AA-/Positive / CRISIL A1+'. The company reported consolidated income of Rs 434.51 crore in Q1 FY27, down from Rs 563.48 crore in Q1 FY26. For the full fiscal year FY26, the company reported a consolidated income of Rs 2,302.64 crore and a profit after tax of Rs 150.12 crore.

What changes now

While the company states no immediate impact on borrowing, the market perception might shift due to the non-cooperative rating status. Investors will look to management for clear communication and assurance regarding their relationship with rating agencies and ongoing operational compliance.

Risks to watch

Key risks include the ongoing scrutiny from USFDA, with five observations issued following an inspection of the Pashamylaram, Hyderabad facility. The financial performance, particularly the shift to a net loss in Q1 FY27, is another area to watch. The company's ability to regain cooperation with rating agencies will also be crucial.

Peer comparison

While specific peer rating actions are not detailed in the filing, companies in the pharmaceutical sector often face scrutiny from USFDA and other international regulators. Performance fluctuations and rating agency relationships are common points of interest for investors in this industry.

Context metrics (time-bound)

• Q1 FY27 Net Loss: Rs 45.19 crore
• Q1 FY26 Profit After Tax: Rs 46.40 crore
• FY26 Consolidated Income: Rs 2,302.64 crore
• FY26 Profit After Tax: Rs 150.12 crore

What to track next

Investors should closely monitor any further disclosures regarding the USFDA observations and the company's engagement with rating agencies. Any signs of improved financial performance in subsequent quarters will also be important.